Market Overview

UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results

Share:
Related RIGL
Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know
3 Covered Call Trades For A Quick Hit (Seeking Alpha)

Jefferies reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but lowered its price target from $21 to $15.

Jefferies noted, "RIGL announced OSKIRA-4 results in which fostamatinib monotherapy failed to show non-inferiority to Humira. In a separate analysis, higher dose regimens of fostamatinib showed superiority against placebo. With $3 in year-end cash and $2 in cash approval milestones if fostamatanib can be approved, we believe the selloff reflects an overly negative Street view on fostamatinib prospects and would be a buyer."

Rigel Pharmaceuticals closed at $8.43 on Wednesday.

Latest Ratings for RIGL

DateFirmActionFromTo
Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight
May 2016JefferiesMaintainsBuy

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!